|Bid||8.52 x 2900|
|Ask||10.72 x 1100|
|Day's Range||8.97 - 9.63|
|52 Week Range||4.65 - 11.24|
|Beta (5Y Monthly)||0.91|
|PE Ratio (TTM)||25.37|
|Earnings Date||Nov 08, 2021 - Nov 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.13|
NASHVILLE, Tenn., September 02, 2021--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for sedation and analgesia, today announced that Harrow Health has provided a $13.5 million senior secured loan to Melt Pharmaceuticals.
NASHVILLE, Tenn. & TOKYO, August 18, 2021--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection.
Last week, you might have seen that Harrow Health, Inc. ( NASDAQ:HROW ) released its second-quarter result to the...